| scholarly article | Q13442814 |
| P356 | DOI | 10.1002/ANA.21057 |
| P698 | PubMed publication ID | 17212356 |
| P50 | author | Wolfgang Wick | Q2591750 |
| Michael Weller | Q2779469 | ||
| Ghazaleh Tabatabai | Q45324636 | ||
| Antje Wick | Q98154405 | ||
| Gabriele von Kürthy | Q117285675 | ||
| P2093 | author name string | Stefan Heckl | |
| Dieter Lemke | |||
| Ulrike Obermüller | |||
| Gunter Christ | |||
| Brigitte Frank | |||
| P433 | issue | 2 | |
| P921 | main subject | adaptive radiation therapy | Q180507 |
| P304 | page(s) | 153-161 | |
| P577 | publication date | 2007-02-01 | |
| P1433 | published in | Annals of Neurology | Q564414 |
| P1476 | title | Synergistic antiglioma activity of radiotherapy and enzastaurin | |
| P478 | volume | 61 |
| Q33399406 | A phase I study of LY317615 (enzastaurin) and temozolomide in patients with gliomas (EORTC trial 26054). |
| Q33388240 | A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas |
| Q48840371 | American Society of Clinical Oncology 2011 CNS tumors update |
| Q37877409 | Anti-angiogenic therapy in glioma |
| Q39641088 | Antitumor activity of enzastaurin as radiation sensitizer in head and neck squamous cell carcinoma. |
| Q34480495 | Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma |
| Q36427538 | Association of Diffusion and Anatomic Imaging Parameters with Survival for Patients with Newly Diagnosed Glioblastoma Participating in Two Different Clinical Trials |
| Q39439133 | Association of early changes in 1H MRSI parameters with survival for patients with newly diagnosed glioblastoma receiving a multimodality treatment regimen |
| Q37533625 | Biology of angiogenesis and invasion in glioma |
| Q38775522 | Clipping the Wings of Glioblastoma: Modulation of WNT as a Novel Therapeutic Strategy |
| Q33688600 | Combinatorial inhibition of Plk1 and PKCβ in cancer cells with different p53 status |
| Q37099594 | Combining molecular targeted agents with radiation therapy for malignant gliomas |
| Q37809861 | Current and emerging molecular targets in glioma |
| Q41860404 | Effects of irradiation on brain vasculature using an in situ tumor model |
| Q37744732 | Effects of irradiation on tumor cell survival, invasion and angiogenesis |
| Q34192330 | Efficacy of the Multi-Kinase Inhibitor Enzastaurin Is Dependent on Cellular Signaling Context |
| Q39776104 | Enzastaurin (LY317615), a protein kinase C beta selective inhibitor, enhances antiangiogenic effect of radiation |
| Q37187715 | Enzastaurin before and concomitant with radiation therapy, followed by enzastaurin maintenance therapy, in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation |
| Q39774778 | Enzastaurin induces H2AX phosphorylation to regulate apoptosis via MAPK signalling in malignant glioma cells |
| Q39956127 | Enzastaurin inhibits tumours sensitive and resistant to anti-EGFR drugs |
| Q33388272 | Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study |
| Q36970534 | Enzastaurin, an inhibitor of PKCbeta, Enhances Antiangiogenic Effects and Cytotoxicity of Radiation against Endothelial Cells |
| Q34718233 | Glioma cell death induced by irradiation or alkylating agent chemotherapy is independent of the intrinsic ceramide pathway |
| Q37993124 | Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma? |
| Q39554437 | Knockdown of vascular endothelial cell growth factor expression sensitizes U251 glioma cells to liposomal paclitaxel and radiation treatment in vitro |
| Q37649471 | MGMT promoter methylation in malignant gliomas: ready for personalized medicine? |
| Q37187383 | Mechanisms of disease: temozolomide and glioblastoma--look to the future |
| Q39946933 | Molecular pathways involved in the synergistic interaction of the PKC beta inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells |
| Q38021521 | Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions |
| Q37107374 | Molecularly targeted therapies for malignant gliomas. |
| Q35021359 | Pathway inhibition: emerging molecular targets for treating glioblastoma |
| Q35570248 | Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma |
| Q33710967 | Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma |
| Q40084195 | Protein kinase C-beta inhibitor enzastaurin (LY317615.HCI) enhances radiation control of murine breast cancer in an orthotopic model of bone metastasis |
| Q37157311 | Protein kinase Cβ as a therapeutic target stabilizing blood-brain barrier disruption in experimental autoimmune encephalomyelitis |
| Q39984715 | The heat shock protein antagonist 17-AAG potentiates the activity of enzastaurin against malignant human glioma cells |
| Q36713503 | Using susceptibility-weighted imaging to determine response to combined anti-angiogenic, cytotoxic, and radiation therapy in patients with glioblastoma multiforme |
| Q52593768 | ω-3 and ω-6 Fatty Acids Modulate Conventional and Atypical Protein Kinase C Activities in a Brain Fatty Acid Binding Protein Dependent Manner in Glioblastoma Multiforme. |
Search more.